• Chloramphenicol in Plasmid Selection: Protocols & Innovation

  2026-07-22

  Chloramphenicol's unique mechanism as a bacterial protein synthesis inhibitor makes it essential for robust plasmid selection and resistance gene mobility studies. Explore evidence-based workflows, troubleshooting insights, and lessons from recent epidemiological research to maximize the reliability and specificity of your molecular biology assays.

• Verapamil HCl Targets TXNIP to Mitigate Osteoporosis: Mechan

  2026-07-22

  This study reveals that the L-type calcium channel blocker Verapamil HCl can reduce osteoporosis by targeting TXNIP, a novel molecular pathway implicated in bone turnover. The findings highlight translational potential for repurposing verapamil in postmenopausal osteoporosis, with mechanistic evidence spanning both osteoclast and osteoblast regulation.

• DiscoveryProbe Natural Product Library Plus: A Platform for

  2026-07-21

  Explore how the DiscoveryProbe Natural Product Library Plus empowers advanced natural product screening for drug discovery. This article uniquely analyzes assay design, mechanistic insights, and translational strategies, with a focus on multidomain applications.

• Precision Phosphorylation Preservation: Transforming Transla

  2026-07-21

  Explore how advanced phosphatase inhibition strategies, anchored by mechanistic insight and recent translational oncology breakthroughs, empower researchers to preserve protein phosphorylation for robust phosphoproteomic analysis. This article offers strategic guidance for leveraging Phosphatase Inhibitor Cocktail 1 (100X in DMSO) in modern workflows and positions APExBIO's solution as a pivotal tool beyond standard protocols.

• AZ505 and SMYD2 Inhibition: New Horizons in Translational Re

  2026-07-20

  This thought-leadership article explores the transformative impact of AZ505, a potent and selective SMYD2 inhibitor, on epigenetic regulation research and translational strategies in disease modeling. Anchored by recent mechanistic insights and validated protocols, it offers strategic guidance for cancer biology and fibrosis investigators seeking to leverage SMYD2 inhibition for next-generation discoveries.

• Flubendazole in Autophagy Research: Mechanistic Precision an

  2026-07-20

  Explore how Flubendazole (methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate) delivers mechanistic clarity and reproducibility to autophagy modulation research. This article uniquely dissects its role in experimental design and interprets pivotal findings for translational cancer biology.

• 2-Hydroxypropyl-β-cyclodextrin: Solubility Protocols & QC Gu

  2026-07-19

  2-Hydroxypropyl-β-cyclodextrin addresses the routine challenge of solubilizing poorly water-soluble, hydrophobic research compounds, particularly those with aromatic or phenyl groups, by forming inclusion complexes that increase aqueous solubility. Its use is well established as a drug formulation excipient or for pharmaceutical solubility improvement; applications beyond these validated workflows lack product or article support.

• BMX Kinase Drives Mtb Survival by Modulating Host Lysosomal

  2026-07-18

  This study uncovers how Mycobacterium tuberculosis (Mtb) manipulates host cell lysosomal acidification to ensure its own intracellular survival, identifying BMX kinase-mediated phosphorylation of ATP6V1E1 as a key regulatory event. The findings suggest that targeting BMX kinase could open new avenues for host-directed therapies against tuberculosis.

• Afatinib in Complex Tumor Models: Precision Tools for ErbB P

  2026-07-17

  Discover how Afatinib (BIBW 2992) enables advanced EGFR, HER2, and HER4 signaling inhibition in physiologically relevant cancer assembloid models. This article uniquely explores protocol parameters, practical assay decisions, and the translational implications of recent breakthroughs for targeted therapy research.

• Triptolide (PG490): Precision Inhibition in Cancer Research

  2026-07-17

  Triptolide (PG490), sourced from APExBIO, delivers nanomolar-range inhibition of transcription and cell invasion, setting a new standard for reproducibility in cancer and immunology assays. Its unique mechanism—targeting IL-2, NF-κB, and RNA polymerase II—enables advanced experimental designs with robust, quantifiable outcomes.

• Scalable EPSC-iMSC EV Production for Pulmonary Fibrosis Ther

  2026-07-16

  Gong et al. present a robust, scalable biomanufacturing platform for producing extracellular vesicles (EVs) from induced mesenchymal stem cells (iMSCs) derived from extended pluripotent stem cells (EPSCs). This work addresses critical challenges in EV therapy standardization and demonstrates in vivo efficacy against pulmonary fibrosis, paving the way for GMP-compliant clinical manufacturing.

• GSK621: AMPK Agonist-Driven Precision in Metabolic Assays

  2026-07-16

  GSK621 stands out as a potent AMPK agonist, enabling researchers to dissect immunometabolic pathways with superior specificity and reproducibility. This article delivers step-by-step guidance, troubleshooting insights, and key innovations from recent literature to help you maximize your experimental outcomes in acute myeloid leukemia and metabolic research.

• Cyclodextrins Suppress TRPV1-Mediated Pain via Cholesterol D

  2026-07-15

  This study demonstrates that β-cyclodextrin derivatives reduce TRPV1 and TRPA1 activation-induced nociception by depleting membrane cholesterol in sensory neurons. The findings introduce a membrane-targeted approach for peripheral analgesia, suggesting an alternative to classical receptor antagonism in pain research.

• HA-siRNA Nanoparticles Target TDRD9 to Alleviate PA Lung Inj

  2026-07-15

  This study introduces hyaluronic acid sodium salt-coated siRNA nanoparticles that target Tudor domain-containing protein 9 (TDRD9) in neutrophils, promoting cuproptosis to reduce Pseudomonas aeruginosa-induced lung injury. The findings reveal a novel therapeutic mechanism for multidrug-resistant pneumonia, expanding the role of extracellular matrix components in immune modulation.

• PUFA-PL Biosynthesis Enzymes Drive Pathogenicity in Rice Bla

  2026-07-14

  This study elucidates how fatty acid desaturase (Fad2) and acyl-CoA synthetase (Acsl4) orchestrate the biosynthesis of polyunsaturated fatty acid-containing phospholipids (PUFA-PLs) in Magnaporthe oryzae, directly linking these enzymes to ferroptosis and fungal pathogenicity. The findings suggest new targets for antifungal strategies by focusing on lipid peroxidation and regulated cell death.

459 records 11/31 page Previous Next First page 上5页 1112131415 下5页 Last page